Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.28 - $2.18
Previous CloseN/A
Volume2.02M
Average Volume (3M)2.37M
Market Cap
$407.01M
Enterprise Value$266.27M
Total Cash (Recent Filing)$139.01M
Total Debt (Recent Filing)$61.45M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Oct 30, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding363,398,860
10 Day Avg. Volume1,633,219
30 Day Avg. Volume2,372,570
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue4.56
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-2.42
Forecast
1Y Price Target
$2.75Price Target Upside154.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Analgesic MarketLX9211 has shown significantly greater reductions in average daily pain score and other pain-related symptoms compared to placebo in clinical trials.
Cardiovascular TreatmentSotagliflozin demonstrated reduced risk of cardiovascular death, major adverse cardiovascular events, and hospitalizations for heart failure, particularly among older adults.
Financial PositionThe exclusive licensing agreement with Novo Nordisk significantly strengthens Lexicon's financial position, providing a cushion that should allow Lexicon to focus resources on pilavapadin's Ph.3 program in DPNP and the Ph.3 SONATA trial for sotagliflozin in Hypertrophic Cardiomyopathy (HCM).
Bears Say
Clinical Trial EfficacyThe Ph.2b PROGRESS study data for pilavapadin in Diabetic Peripheral Neuropathic Pain (DPNP) shows modest efficacy versus placebo.
Research And DevelopmentLexicon has notably lowered its FY2025 operating expense guidance, primarily driven by a revised R&D expense projection, largely due to the transfer of costs to Novo Nordisk under the licensing agreement.
Treatment EfficacyThere is significant unmet need in the DPNP therapeutic space as current treatments focus on symptoms without addressing the root cause, and LX9211 aims to fill this gap.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $2.17 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $407.01M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.085.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 363,398,860 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (154.63% Upside)
$2.75 (154.63% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.91%
12-Months-Change
Fundamentals
Return on Equity
-65.30%
Trailing 12-Months
Asset Growth
-39.58%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of human disease. The company primarily operates in the pharmaceutical sector, specializing in drug development for conditions such as metabolic and neurodegenerative diseases. Lexicon's core products include LX9211, a treatment for diabetic neuropathic pain, and LX2761, aimed at addressing type 1 diabetes, among others.
LXRX Company Deck
LXRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Lexicon Pharmaceuticals was largely positive, marked by significant revenue growth, successful strategic repositioning to an R&D-focused company, and promising advancements in the drug pipeline. However, challenges remain in terms of reduced cash reserves and the dependence on partnerships for future progress.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$2.75
▲(154.63% Upside)
Technical Analysis
Protalix
―
DBV Technologies SA - American
―
Gossamer Bio
―
Foghorn Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
13.05% Insiders
8.92% Mutual Funds
49.87% Other Institutional Investors
25.31% Public Companies and
Individual Investors